[go: up one dir, main page]

MX2019009908A - Combinacion de un agonista de ppar con un agonista de fxr. - Google Patents

Combinacion de un agonista de ppar con un agonista de fxr.

Info

Publication number
MX2019009908A
MX2019009908A MX2019009908A MX2019009908A MX2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A MX 2019009908 A MX2019009908 A MX 2019009908A
Authority
MX
Mexico
Prior art keywords
agonist
combination
ppar
fxr
fxr agonist
Prior art date
Application number
MX2019009908A
Other languages
English (en)
Other versions
MX382537B (es
Inventor
Noel Benoît
Walczak Robert
Belanger Carole
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2019009908A publication Critical patent/MX2019009908A/es
Publication of MX382537B publication Critical patent/MX382537B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación de principios activos para su uso en el tratamiento de enfermedades.
MX2019009908A 2017-02-21 2018-02-21 Combinacion de un agonista de ppar con un agonista de fxr MX382537B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17157279 2017-02-21
EP17162161 2017-03-21
EP17165131 2017-04-05
PCT/EP2018/054305 WO2018153933A1 (en) 2017-02-21 2018-02-21 Combination of a ppar agonist with a fxr agonist

Publications (2)

Publication Number Publication Date
MX2019009908A true MX2019009908A (es) 2019-10-14
MX382537B MX382537B (es) 2025-03-13

Family

ID=61223919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009908A MX382537B (es) 2017-02-21 2018-02-21 Combinacion de un agonista de ppar con un agonista de fxr

Country Status (15)

Country Link
US (1) US20200054589A1 (es)
EP (1) EP3585374B1 (es)
JP (1) JP7618384B2 (es)
KR (1) KR20190117632A (es)
CN (1) CN110300580A (es)
AU (1) AU2018223146B2 (es)
CA (1) CA3051776A1 (es)
ES (1) ES2959842T3 (es)
IL (1) IL268426A (es)
MX (1) MX382537B (es)
NZ (1) NZ756329A (es)
PH (1) PH12019501905A1 (es)
SG (1) SG11201906987RA (es)
WO (1) WO2018153933A1 (es)
ZA (1) ZA201906100B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
MA55592A (fr) * 2019-04-10 2022-02-16 Genfit Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1
US12528791B2 (en) 2019-08-23 2026-01-20 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP4149452A4 (en) * 2020-05-13 2024-05-01 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
IL298145A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combined treatment of liver disorders
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
WO2022051321A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
EP4210705A4 (en) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. SOLID DISPERSION FORMULATIONS OF A FXR AGONIST
TWI845975B (zh) * 2021-07-06 2024-06-21 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
CA3227149A1 (en) * 2021-08-13 2023-02-16 Alebund Pharmaceuticals (Hong Kong) Limited Deuterated compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT364688B (de) 1979-07-19 1981-11-10 Gergely Gerhard Verfahren zur herstellung eines aromaproduktes
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
WO2004046162A2 (en) 2002-11-14 2004-06-03 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PL2029547T3 (pl) 2006-05-24 2010-09-30 Lilly Co Eli Agoniści FXR
BRPI0711875A2 (pt) 2006-05-24 2012-01-10 Lilly Co Eli compostos e métodos para modular os fxr
JP4970538B2 (ja) 2006-06-29 2012-07-11 エフ．ホフマン−ラ ロシュ アーゲー ベンゾイミダゾール誘導体、それらの製造方法、ｆｘｒアゴニストとしてのそれらの使用及びそれらを含む製剤
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
AU2008266154A1 (en) 2007-06-13 2008-12-24 Claxosmithkltne Llc Farnesoid X receptor agonists
CN101877966A (zh) 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
JP5204232B2 (ja) 2007-08-27 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー Ｆｘｒアゴニストとして使用されるベンゾイミダゾール誘導体
BRPI0818813A2 (pt) 2007-11-15 2015-04-22 Hoffmann La Roche Compostos derivados de metil-benzimidazol, processo para a manufatura desses compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ ou profilático de enfermidades que são afetadas por moduladores de fxr e uso de tais compostos
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
KR101444988B1 (ko) 2008-09-25 2014-09-26 에프. 호프만-라 로슈 아게 3-아미노-인다졸 또는 3-아미노-4,5,6,7-테트라하이드로-인다졸 유도체
EP2344459B1 (en) 2008-09-25 2013-12-25 F. Hoffmann-La Roche AG 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8309581B2 (en) 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
EP2571843B1 (en) 2010-05-17 2017-12-27 Genfit Improved preparation of chalcone derivatives
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2843737T3 (es) 2013-05-14 2021-07-20 Intercept Pharmaceuticals Inc Derivados sustituidos con 11-hidroxilo-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores de receptor de farnesoide X
KR20160132111A (ko) 2014-03-13 2016-11-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Fxr 작용제와 제조방법 및 용도
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3253382B1 (en) * 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
US20180117013A1 (en) * 2015-03-26 2018-05-03 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives

Also Published As

Publication number Publication date
JP7618384B2 (ja) 2025-01-21
AU2018223146B2 (en) 2023-12-21
JP2020508316A (ja) 2020-03-19
MX382537B (es) 2025-03-13
CA3051776A1 (en) 2018-08-30
AU2018223146A1 (en) 2019-09-05
ZA201906100B (en) 2023-08-30
US20200054589A1 (en) 2020-02-20
CN110300580A (zh) 2019-10-01
PH12019501905A1 (en) 2020-06-08
WO2018153933A1 (en) 2018-08-30
EP3585374B1 (en) 2023-07-19
IL268426A (en) 2019-09-26
KR20190117632A (ko) 2019-10-16
ES2959842T3 (es) 2024-02-28
NZ756329A (en) 2025-09-26
SG11201906987RA (en) 2019-09-27
EP3585374A1 (en) 2020-01-01
BR112019017312A2 (pt) 2020-04-14

Similar Documents

Publication Publication Date Title
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
UY35731A (es) Éteres de arilo y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
CO2019003162A2 (es) Formas cristalinas y salinas de compuestos agonistas de ppar
MX384989B (es) Uso de un agonista del receptor x retinoide (rxr) en combinación con una hormona tiroidea para el tratamiento de esclerosis múltiple.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
MX375860B (es) Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.